-
Mashup Score: 7
PURPOSEThe TRK inhibitor larotrectinib is US Food and Drug Administration approved for NTRK fusion–positive solid tumors that lack a satisfactory alternative or have progressed after treatment but has not been systematically studied as a frontline therapy …
Source: ascopubs.orgCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 4
PURPOSE The adjuvant treatment for stage III colon cancer (CC) is chemotherapy combining fluoropyrimidine (FP) and oxaliplatin (OX). FP regimen plus OX (FPOX) may benefit in high-risk stage II CC. We performed a pooled analysis of pivotal MOSAIC and C-07 studies evaluating FPOX for the treatment of high-risk stage II CC according to prognostic factors, number of high-risk factors, and current clinicopathologic risk classification on the basis of T stage, tumor perforation, and number of lymph nodes examined. PATIENTS AND METHODS One thousand five hundred and ninety-five patients with stage II CC receiving FP or FPOX were pooled. The overall survival (OS) benefit of OX was analyzed using Kaplan-Meier curves and unadjusted Cox models stratified by study. Three thousand and fifty-nine patients with stage III CC were used only for interaction tests between the allocated chemotherapy and stage. RESULTS In the pooled analysis of stage II patients, independent prognostic factors in multivaria
Source: ascopubs.orgCategories: General Medicine News, Onc News and JournalsTweet-
Assessment of the Addition of Oxaliplatin to Fluoropyrimidine-Based Adjuvant #Chemotherapy in Patients With High-Risk Stage II #ColonCancer: An ACCENT Pooled Analysis: https://t.co/NNER8ra95p #crcsm #gicsm
-
-
Mashup Score: 1
PURPOSEThe use of anti–B-cell maturation antigen (BCMA) chimeric antigen receptor T-cell (CART) therapy for AL amyloidosis (AL) is limited owing to patient frailty. HBI0101 anti-BCMA CART was the first proof of concept for its applicability to AL. This …
Source: ascopubs.orgCategories: General Medicine News, Oncologists1Tweet-
Efficacy and Safety of Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor T-Cell for the Treatment of Relapsed and Refractory AL Amyloidosis: https://t.co/7qgeAgzIus
-
-
Mashup Score: 2
PURPOSEThe AMPLIFY trial recently established fixed-duration acalabrutinib, venetoclax, and obinutuzumab (AVO) as a new standard-of-care option for patients with previously untreated chronic lymphocytic leukemia (CLL) with wild-type TP53; however, due to …
Source: ascopubs.orgCategories: General Medicine News, Oncologists1Tweet-
Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial: https://t.co/NZiZKoRMJN Authored by @Jneoptolemos et al.
-
-
Mashup Score: 2Submit Manuscript | ASCO Publications - 10 day(s) ago
Authors must submit all new manuscripts using the online Manuscript Processing System (Editorial Manager). Before submitting, authors should ensure their manuscript complies with the information provided in our Journal policies. For Journal of Clinical Oncology (JCO) only, there is an $80 USD submission fee for Original Reports. ASCO Journals have adopted a format-free submission policy (EZSubmit). New submissions are not scrutinized for compliance with our formatting guidelines (reference style, order
Source: ascopubs.orgCategories: General Medicine News, Onc News and JournalsTweet-
⌚There's still time to request simultaneous publication in #JCO Journals with your #GI25 presentation! Submit by December 19th or send an inquiry to pubs@asco.org. Learn more: https://t.co/xJoucWnF5d
-
-
Mashup Score: 1Influence of Nucleophosmin (NPM1) Genotypes on Outcome of Patients With AML: An AIEOP-BFM and COG-SWOG Intergroup Collaboration - 11 day(s) ago
PURPOSESeveral genomic subsets of NPM1 mutations with varying sequences (type A, B, D, etc) have been identified. Despite molecular heterogeneity, NPM1 mutations cumulatively portend a more favorable outcome, but biology and prognostic implications of …AML patients with NPM1 type D mutations show markedly poorer overall survival compared with other variants.
Source: ascopubs.orgCategories: General Medicine News, Oncologists1Tweet-
Influence of Nucleophosmin (NPM1) Genotypes on Outcome of Patients With #AML: An AIEOP-BFM and COG-SWOG Intergroup Collaboration https://t.co/st6jVU2yea Authored by @MartinaPigazzi et al. #leusm https://t.co/MV8zb8iaK0
-
-
Mashup Score: 7
PURPOSEMixed formulation of fosrolapitant and palonosetron (PALO), HR20013, is a novel fixed-dose intravenous antiemetic combination that could simultaneously antagonize neurokinin-1 and 5-hydroxytryptamine-3 receptors. This study was designed to evaluate …HR20013, a novel fixed-dose dual-pathway antiemetic, prevents CINV in patients receiving cisplatin-based HEC.
Source: ascopubs.orgCategories: General Medicine News, Oncologists1Tweet-
Randomized, Phase III Trial of Mixed Formulation of Fosrolapitant and Palonosetron (HR20013) in Preventing Cisplatin-Based Highly Emetogenic #Chemotherapy-Induced Nausea and Vomiting: PROFIT https://t.co/ZryHpNyC0w #PallOnc https://t.co/zJm0kXPYhK
-
-
Mashup Score: 14
PURPOSEClinicopathological factors and the 21-gene Oncotype DX Breast Recurrence Score (RS) test both influence prognosis. Our goal was to develop a new tool, RSClinN+, to individualize recurrence risk and chemotherapy benefit predictions by menopausal …
Source: ascopubs.orgCategories: General Medicine News, Oncologists1Tweet-
Development and Validation of the RSClinN1 Tool to Predict Prognosis and #Chemotherapy Benefit for Hormone Receptor-Positive, Node-Positive Breast Cancer: https://t.co/JK1phTvGhd #bcsm https://t.co/UNgeyhCqo9
-
-
Mashup Score: 1
PURPOSEHuman epidermal growth factor receptor 2 (HER2)–targeted therapy is standard of care for HER2-positive (HER2+) breast cancer, but most patients develop progressive disease with persistent HER2 expression. No definitive treatment guidance currently …Treatment of patients with pretreated HER2+ MBC with T-Duo ADC versus physician’s choice in TULIP phase III trial.
Source: ascopubs.orgCategories: General Medicine News, Oncologists1Tweet-
Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic #BreastCancer: An Open-Label, Randomized, Phase III Trial (TULIP) https://t.co/3yWNYLEutp #bcsm
-
-
Mashup Score: 1Submit Manuscript | ASCO Publications - 14 day(s) ago
Authors must submit all new manuscripts using the online Manuscript Processing System (Editorial Manager). Before submitting, authors should ensure their manuscript complies with the information provided in our Journal policies. For Journal of Clinical Oncology (JCO) only, there is an $80 USD submission fee for Original Reports. ASCO Journals have adopted a format-free submission policy (EZSubmit). New submissions are not scrutinized for compliance with our formatting guidelines (reference style, order
Source: ascopubs.orgCategories: General Medicine News, Onc News and JournalsTweet-
⌚There's still time to request simultaneous publication in #JCO Journals with your #GI25 presentation! Submit by December 19th or send an inquiry to pubs@asco.org. Learn more: https://t.co/xJoucWnF5d
-
Larotrectinib for Newly Diagnosed Infantile Fibrosarcoma and Other Pediatric NTRK Fusion–Positive Solid Tumors (Children’s Oncology Group ADVL1823): https://t.co/DphG9CGG3g #childhoodcancer #pedcsm